U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07130695) titled 'Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation' on Aug. 07.
Brief Summary: Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in survival.
Study Start Date: Oct. 31
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Intervention:
DRUG: Olutasidenib Investigational Agent Administration
Twice daily olutasidenib maintenance therapy
Recrui...